Xylem, a global water technology company announced it has completed its acquisition of Evoqua Water Technologies, a leader in mission-critical water treatment solutions and services, in an all-stock transaction valued at about US$7.5bn. The combination creates an advanced platform of capabilities to address customers’ and communities’ critical water challenges.
Headquartered in Washington DC, US, the combined company becomes what is said to be the world’s largest pure-play water technology company, with $7.3bn in pro forma revenue and more than 22,000 employees globally. Xylem’s portfolio of solutions across the water cycle, including integrated services and deep application expertise, will help customers in utilities, industrial and commercial end markets address their pressing water needs.
“Global awareness of water as a systemic risk to society has never been greater. Investment in water solutions continues to accelerate as communities and businesses around the world address intensifying challenges like water scarcity, quality and resilience to climate change — and how to address these issues in an affordable way,” said Patrick Decker, its president and CEO. “Our combination with Evoqua creates a global platform to solve these critical water challenges at a greater scale. Together, we are positioned to help meet customers’ mission-critical needs with a portfolio of products and services across the water cycle.”
The combined company’s executive leadership team will be led by Decker and include senior leaders from both Xylem and Evoqua. Xylem has also appointed Lisa Glatch and Lynn Swann, former Evoqua directors, to serve as members of its board of directors. Glatch brings a strategic and financial perspective and more than 30 years’ experience in senior leadership roles across the public and private sectors in the energy, chemicals, environmental, water and transportation industries. Swann has held various leadership roles across business, government, and philanthropic organisations and is an experienced member of public company boards.
Under the terms of the transaction, each share of Evoqua common stock was converted into the right to receive 0.48 of a share of Xylem common stock. This results in Xylem shareholders owning about 75% and Evoqua shareholders owning approximately 25% of the combined company on a fully diluted basis.